Muley, T.;Schneider, M.;Meister, M.;Thomas, M.;Heussel, C.;Kriegsmann, M.;Holdenrieder, S.;Wehnl, B.;Rolny, V.;Mang, A.;Gerber, R.;Herth, F.
Serum Biomarkers Enhance Prognostic Value of Computed Tomography (CT) in Patients With Non-Small Cell Lung Cancer (NSCLC)
J Thorac Oncol
2021
16 Suppl S
10
S1028-S1029

Nassar, Y. M.;Ojara, F. W.;Holdenrieder, S.;Krueger, K.;Joerger, M.;Michelet, R.;Huisinga, W.;Kloft, C.
Prognostic impact of five serum biomarkers in patients with advanced non-small cell lung cancer (NSCLC): An exploratory analysis
Ann Oncol
2021
32 Suppl 5
S404-S404

Saafan, Hisham;Alahdab, Ahmad;Michelet, Robin;Gohlke, Linus;Ziemann, Janine;Holdenrieder, Stefan;McLaughlin, Katie-May;Wass, Mark N;Cinatl, Jindrich;Michaelis, Martin;Kloft, Charlotte;Ritter, Christoph A
Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line.
Cells
2021
10
4

Oezcueruemez, Mustafa;Katsounas, Antonios;Holdenrieder, Stefan;von Meyer, Alexander;Renz, Harald;Woelfel, Roman
Assessment of SARS-CoV-2 rapid antigen tests
J. Lab. Med.
2021
45
3
143-148

Garrido, Manuel M;Marta, José C;Ribeiro, Ruy M;Pinheiro, Luís C;Holdenrieder, Stefan;Guimarães, João T
Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations.
In Vivo
2021
35
6
3431-3439

Garrido, Manuel M;Ribeiro, Ruy;Pinheiro, Luís C;Holdenrieder, Stefan;Guimarães, João T
The prostate health index and the percentage of [-2]proPSA maintain their diagnostic performance when calculated with total and free PSA from different manufacturers.
Clin Chem Lab Med
2021
59
11
1869-1877

Handke, Nikolaus A;Rupp, Alexander B A;Trimpop, Nicolai;von Pawel, Joachim;Holdenrieder, Stefan
Soluble High Mobility Group Box 1 (HMGB1) Is a Promising Biomarker for Prediction of Therapy Response and Prognosis in Advanced Lung Cancer Patients.
Diagnostics (Basel)
2021
11
2

Özgür, Emre;Mayer, Zsuzsanna;Keskin, Metin;Yörüker, Ebru E;Holdenrieder, Stefan;Gezer, Ugur
Satellite 2 repeat DNA in blood plasma as a candidate biomarker for the detection of cancer.
Clin Chim Acta
2021
514
74-79

Lambing, S.;Holdenrieder, S.;Mueller, P.;Hagen, C.;Garbe, S.;van den Boorn, J. G.;Bartok, E.;Renn, M.;Hartmann, G.
Enhanced efficacy of combinatorial RIG-I-mediated immunotherapy and radiotherapy in malignant melanoma depends on functional p53 expression
Naunyn Schmiedebergs Arch Pharmacol
2021
394 Suppl 1
SUPPL 1
S14-S14

Cavalier, Etienne;Guiot, Julien;Lechner, Katharina;Dutsch, Alexander;Eccleston, Mark;Herzog, Marielle;Bygott, Thomas;Schomburg, Adrian;Kelly, Theresa;Holdenrieder, Stefan
Circulating Nucleosomes as Potential Markers to Monitor COVID-19 Disease Progression.
Front Mol Biosci
2021
8